Adjunctive therapies for AIDS dementia complex
Editorial Group: Cochrane HIV/AIDS Group
Published Online: 16 JUL 2008
Assessed as up-to-date: 11 FEB 2007
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Uthman OA, Abdulmalik JO. Adjunctive therapies for AIDS dementia complex. Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No.: CD006496. DOI: 10.1002/14651858.CD006496.pub2.
- Publication Status: New
- Published Online: 16 JUL 2008
AIDS dementia complex is a common complication of human immunodeficiency virus type 1 (HIV-1) that continues to exist despite the current use of potent antiretroviral therapy. It is a source of great morbidity and, when severe, is associated with limited survival.
To determine efficacy and safety of adjunctive therapies for AIDS dementia complex
We searched the Cochrane HIV/AIDS group trials Specialized Register (December 2006), the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 1, 2007), MEDLINE (January 1980 to February 2007), EMBASE (January 1980 to February 2007), AIDSearch (January 1980 to February 2007), PsycINFO (January 1980 to February 2007), PSYCHLIT (January 1980 to February 2007), LILACS (January 1980 to February 2007), conference proceedings, trial registers, theses databases, and reference lists of the articles. We also contacted manufacturers and researchers in the field.
Randomized controlled trials, either published or published, that compared one type of adjunctive therapy to no therapy or placebo in adults with AIDS dementia complex
Data collection and analysis
Two authors independently assessed trials quality, extracted data and entered data into RevMan 4.2 software. Where possible intention-to-treat data were used and we contacted study authors for additional information. We collected neurocognitive performance, adverse effects, tolerability and all-cause mortality information from the trials.
Ten trials involving 711 people were included. All the studies were phase 2 trials. Six studies used adequate methods for allocation of sequence generation and unclear in the remaining four trials. Allocation concealment was adequate in five trials and unclear in the remaining trials. The trials were heterogeneous in terms of types, dosages, routes and frequencies of administration of the adjunctive therapies. There were no significant differences between the treated and placebo groups on neuropsychological test scores, number of those that complete the assign dosage of experimental medication, adverse effects, and all-cause mortality.
This review confirms the absence of evidence that any of the adjunctive therapies improves cognitive performance or quality of life, or both for patients with ADC, though they were well tolerated and safe.
Plain language summary
There is no evidence that adjunctive therapies for AIDS dementia are effective, though they are well-tolerated and safe.
The authors did a systematic review of ten studies, to see if adjunctive therapies (supplemental to the main treatment) for AIDS dementia were effective and safe. They found no evidence that adjunctive therapies had any effect on the patients They did find adjunctive therapies to be safe, and without any harmful effect on the patients.
愛滋病癡呆複合症狀(AIDS dementia comples)之附屬治療
我們搜尋了Cochrane HIV/AIDS group trials Specialized Register (December 2006), the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 1, 2007), MEDLINE (January 1980 to February 2007), EMBASE (January 1980 to February 2007), AIDSearch (January 1980 to February 2007), PsycINFO (January 1980 to February 2007), PSYCHLIT (January 1980 to February 2007), LILACS (January 1980 to February 2007), 會議程序，臨床試驗登錄，資料庫，文章的引用出處。我們也聯絡了此領域的製造商與研究者。
2 位作者分別獨立評估試驗的品質，抽取資料並輸入RevMan 4.2 software。進行“意向分析”，並與各個試驗之作者聯繫獲取額外的資料。我們從各個試驗中收集了神經認知表現，藥物副作用，藥物耐受性及各種原因的死亡率。
此翻譯計畫由臺灣國家衛生研究院(National Health Research Institutes, Taiwan)統籌。